Where ProQR Therapeutics Stands With Analysts
Analysts have provided the following ratings for ProQR Therapeutics (NASDAQ:PRQR) within the last quarter:
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $18 to $8.
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $20 to $4.
78 Biggest Movers From Friday
Gainers
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) surged 26% to close at $2.24. Y-mAbs reported completion of pre-BLA meeting with the FDA for Omburtamab.
Mid-Day Market Update: Nasdaq Drops 100 Points; Bloom Energy Shares Jump
The Nasdaq turned lower during the mid-day session, with the tech-laden index falling 100 points on Friday.
41 Stocks Moving In Friday’s Mid-Day Session
Gainers
Modular Medical, Inc. (NASDAQ: MODD) shares climbed 34.5% to $4.99 following its recent uplisting to the Nasdaq Capital Market on Thursday.
Mid-Morning Market Update: Markets Open Higher As Dow Rises Over 100 Points
U.S. stocks opened on a strong note on Friday, after recording sharp losses in the previous session.
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly’s Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours:
ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder
ProQR Therapeutics N.V. (NASDAQ: PRQR) shares are plunging after